"Tirzepatide versus Insulin Glargine in Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4): A Randomised, Open-Label, Parallel-Group, Multicentre, Phase 3 Trial." The Lancet, 2021, 398(10313), 1811-1824
DOI: 10.1158/1078-0432.CCR-08-2867 J
They can include temporary flushing, headache, or tingling at the injection site
Held from February 26 to 28, 2026, at the Moscone Center in San Francisco, California (USA), the symposium is a reference point for the presentation of new scientific data, results fr Trastuzumab deruxtecan (T-DXd) Provides Significant Clinical Benefit Over Trastuzumab emtansine (T-DM1), Marking a Potential Shift in the Therapeutic Standard for HER2+ Breast Cancer Breast cancer is the second most common type of cancer and one of the leading causes of cancer-related death worldwide